Chronic hepatitis C virus (HCV) infection is a common condition that affects more than 2.7 million individuals in the US.1 New direct acting antiviral (DAA) treatments offer an unprecedented opportunity to cure HCV. In clinical trials as well as clinical practice, DAA treatments have resulted in sustained virological response (SVR–a surrogate for virological cure) in 90-100% of patients.2–8 The population-level effectiveness of DAA remains limited by low rates of HCV case screening and identification9.